US 11,771,711 B2
Substituted pyridines as DNMT1 inhibitors
Andrew B. Benowitz, Stevenage (GB); David T. Fosbenner, Collegeville, PA (US); Bryan Wayne King, Collegeville, PA (US); and Stuart Paul Romeril, Collegeville, PA (US)
Assigned to GlaxoSmith Kline Intellectual Property Development Limited, Middlesex (GB)
Filed by GlaxoSmithKline Intellectual Property Development Limited, Brentford (GB)
Filed on Oct. 14, 2022, as Appl. No. 17/966,504.
Application 17/966,504 is a continuation of application No. PCT/IB2022/051637, filed on Feb. 24, 2022.
Claims priority of provisional application 63/155,325, filed on Mar. 2, 2021.
Prior Publication US 2023/0101987 A1, Mar. 30, 2023
Int. Cl. A61K 31/675 (2006.01); A61P 35/02 (2006.01); A61K 31/44 (2006.01); C07D 213/85 (2006.01); C07F 9/58 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 31/44 (2013.01); A61P 35/02 (2018.01); C07D 213/85 (2013.01); C07F 9/58 (2013.01); C07B 2200/13 (2013.01)] 17 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
or a prodrug or a pharmaceutically acceptable salt thereof.